A 7-yr-old girl with high density lipoprotein (HDL) deficiency and xanthomas has been identified in a Turkish kindred with repetitive consanguinity. She has severely reduced HDL-cholesterol and no apolipoprotein (apo) A-I. ApoA-II is reduced, whereas apoA-IV and apoC-III are normal. ApoB and low density lipoprotein (LDL)-cholesterol are increased. This is reflected in hypercholesterolemia. VLDL and IDL particles are low, and serum triglycerides are normal. The genetic defect could be identified as a base insertion into the third exon of the apoA-I gene. This leads to a nonsense peptide sequence beginning at amino acid 5 of the mature plasma protein and early termination of translation. The patient is homozygous for this mutation. Pedigree analysis indicated an autosomal dominant inheritance with no evidence of another genetic defect of lipoprotein metabolism in the kindred. In HDL deficiency, HDL binding to leukocytes was increased compared to normal. In the postprandial state, binding of labeled HDL3 to leukocytes is unchanged. This is in contrast to results with postprandially isolated leukocytes from controls or Tangier patients, which have a reduced binding capacity for HDL3. These results indicate that postprandial HDL precursors may compete the binding of labeled HDL3. The metabolic consequences of HDL deficiency were analyzed.
Introduction
HDL are part of the plasma lipoprotein system ( 1 ). They have attracted much scientific attention in recent years, because epidemiologic data indicate an inverse correlation between HDL- cholesterol and the risk for premature cardiovascular disease (2) (3) (4) (5) . Furthermore, it could be shown that infusion ofhomologous HDL may reduce atheroma formation and induce atheroma regression in a rabbit model of atherogenesis (6, 7) . Transgenic mice overproducing human apoA-I, the major apolipoprotein of HDL, are less susceptible to atherosclerosis (8) . The mechanism of this protective effect is not known in detail.
One major function of HDL in lipid metabolism is its role as acceptor of excess cellular cholesterol which cannot be degraded by nonhepatic cells. This function is the first step in "reverse" cholesterol transport from peripheral tissues to the liver, and is currently the prime candidate for the vasoprotective effects of HDL. The mechanism, by which HDL takes up cellular cholesterol is a matter of intensive investigation. Evidence for receptor independent and receptor-mediated pathways possibly involving endocytosis or activation of second messenger systems has been found, and several models have been proposed that have been reviewed recently (3, 9, 10) . Besides HDL and its apolipoproteins the enzymes lecithin/ cholesteryl acyltransferase (LCAT)' and hepatic lipase (HL), and cholesteryl ester transfer protein (CETP) take part in reverse cholesterol transport (3).
The two major apolipoproteins of HDL, apoA-I and apoA-II, are both synthesized as preproproteins (1 1, 12) . Whereas apoA-I is synthesized in the small intestine and the liver, apoA-II is synthesized exclusively in the liver. Both genes have been cloned and their chromosomal localization has been determined (13) (14) (15) (16) . The apoA-I gene is found on chromosome 11 in a gene cluster with apoC-11 and apoA-IV ( 17 ) . The apoA-II gene is located on the long arm of chromosome 1 ( 18, 19) .
Precursors of HDL are secreted from the intestine (20) and liver (21) . Nascent HDL particles from the liver appear as discoidal particles in the plasma compartment, where they are converted to spherical HDL particles (22) . The intestinally derived precursors are rich in apoA-I and apoA-IV, whereas the liver derived precursors contain predominantly apoA-I, apoA-II, and apoE. Their major lipid components are phospholipids. In addition to direct synthesis, HDL precursors are formed during lipolysis of triglyceride-rich lipoproteins as so-called "surface remnants" (3) . HDL precursors are transformed to larger cholesterol enriched spherical HDL particles after interaction with peripheral cells and several enzymes and proteins such as LCAT, HL, and CETP.
Several HDL deficiency syndromes have been described recently (for review see references [23] [24] [25] . They may be subdivided into three major groups. One is the asynthetic or hypo-synthetic type, in which there is decreased or absent production of HDL particles. The second is the hypercatabolic type, with Tangier disease as the best-known example. In this disease, there is rapid catabolism ofHDL due to a defect in intracellular lipid traffic (25) . In addition, there are HDL deficiencies caused by enzyme defects such as LCAT deficiency or fish-eye disease (26) . Finally, there is a large group of kindreds with decreased HDL of unknown etiology (23) .
In most cases HDL deficiency is not linked to the apoA-I or apoA-II genes. However, in some asynthetic cases the genetic defect could be elucidated at the DNA level (27) (28) (29) (30) . Two of these cases showed major rearrangements ofthe apoA-I/C-III/ A-IV gene locus on chromosome 11 leading to a complete lack of apoA-I synthesis. In one case the apoA-I and apoC-III genes were involved (27) ; in the other case all three genes were affected (28). In both cases the homozygous probands had severe cardiovascular disease at an early age. Two other cases have been elucidated at the gene level. One of these is caused by a point mutation in the apoA-I gene and is associated with premature cardiovascular disease (29) . The other has a frameshift mutation in the carboxy-terminal region ofapoA-I. Phenotypically this patient resembles LCAT deficiency. The patient has so far no signs of cardiovascular disease (30) . These genetic syndromes provide additional evidence for the importance of HDL for the protection from atherosclerosis. Interestingly, the absence of apoA-II due to a splice junction mutation does not lead to hypoalphalipoproteinemia nor to cardiovascular disease (31 ) .
In addition to HDL deficiency, there have been reports of hyperalphalipoproteinemia. In some cases further information on the genetic abnormality is available. Deficiency of CETP has been shown to lead to increased serum HDL. In this case, defective transfer of cholesteryl esters from HDL to apoB-containing particles leads to accumulation of cholesteryl esters in HDL and an increase in total HDL cholesterol and apolipoproteins (32, 33) . Furthermore, there have been reports of hyperalphalipoproteinemia associated with overproduction ofapoA-I, increased activity oflipoprotein lipase, and decreased activity of hepatic triglyceride lipase (34) (35) (36) .
In this report, a new case of HDL deficiency with plane xanthomas is presented, and the biochemical, genetic, and metabolic abnormalities are analyzed.
Methods
Fractionation and analysis of serum lipoproteins. Lipoproteins were isolated by sequential ultracentrifugation (model L8-70 ultracentrifuge, Beckman Instruments, Inc., Fullerton, CA) using a 50.3Ti or 7OTi rotor. Lipoprotein fractions were extensively dialyzed to remove excess KBr. Total cholesterol, free cholesterol, triglycerides, and phospholipids were measured by enzymic methods (Boehringer Mannheim GmbH, Mannheim, FRG) (37) . ApoA-I, apoA-II, and apoB were determined by a turbidimetric method (Behring, Marburg, FRG). ApoA-IV, apoC-II, apoC-III, and apoE were determined by sandwichtype ELISA. HDL-apolipoproteins were further analyzed by SDS-gel electrophoresis and Western blot as described (37) .
Southern blotting. Genomic DNA was isolated from white blood cells as described ( 16) . Restriction endonucleases were purchased from Boehringer Mannheim, and DNA was cleaved with 3-5 U of enzyme per jg of DNA under the conditions specified by the manufacturer. Electrophoresis in 0.7% agarose gels, Southern transfer, and hybridization with radiolabeled cDNA for apoA-I have been described previously ( 16 (38) . Agarose gel electrophoresis, Northern transfer and hybridization to radiolabeled cDNA were performed using standard protocols (39) .
Construction of a genomic library and screening. Genomic DNA was cleaved with BamHI to completion, extracted with phenol, and ethanol precipitated. Without further size fractionation, a partial genomic library was constructed by inserting BamHI fragments into the cloning site of EMBL3 (40). The library was screened for apoA-I clones as described ( 16, 39) .
DNA sequencing. Fragments from one recombinant apoA-I clone were subcloned into M 13 and sequenced by the dideoxy chain terminating method (41) using a commercially available kit (Gibco-BRL, Gaitherburg, MD). PCR-fragments of exon 3 of the patient's DNA were sequenced after subcloning into pUC 18.
Oligonucleotide melting. A 20-mer oligonucleotide with the sequence ofthe mutant HDL-deficiency allele was synthesized and designated PI. The sequence was 5' GATGAACCCCCCCCAGAGCC 3'. It was used for oligonucleotide melting with either total genomic DNA or genomic DNA after amplification (42) . PI was 5'-end labeled to high specific activity with [_-32P]ATP (7,000 Ci/mmol, New England Nuclear, Boston, MA) using polynucleotide kinase (Boehringer Mannheim). In preliminary experiments the hybridization properties of PI to cloned normal and mutant apoA-I DNA were established. Hybridization was performed after transfer of DNA to nitrocellulose in 6
x SSC, 5 X Denhardt's, 0.1% SDS, 100 jug/ml salmon sperm DNA at 500C for 16-18 h. Filters were then washed in 6 x SSC, 0.1% SDS once briefly at room temperature, followed by 20 min at 550C, and 20 min at 60'C. At 550C washing temperature PI binds to both the normal and the mutant apoA-I allele. At 60'C washing temperature it binds only to the perfectly complementary mutant apoA-I allele.
DNA amplification. A 317 bp fragment containing exon 3 of the apoA-I gene was amplified from genomic DNA using two oligonucleotides complementary to sequences in intron 2 and 3: P2, 5' CAAGCT-TGGCCTTTCGGCTCA 3'; P3, 5' ACTCGGCCAGTCTGGCTT-CAA 3'. Annealing and extension were performed at 580C for 5 min, melting at 940C for 1, 5 min. The amplified DNA was blotted to nitrocellulose using a manifold (Minifold II, Schleicher & Schuell Inc., Keene, NH) and hybridized with 32P-labeled PI as described above.
Serumfractionation by gelfiltration. Serum was fractionated by gel filtration on a Hiload 16/60 Superdex 200 prep grade column using fast protein liquid chromatography (FPLC, Pharmacia, Uppsala, Sweden) as described previously (43) . 200 ,l of serum was applied to the column and eluted at 4VC with 50 mM sodium-phosphate, 150 mM NaCI, 1 mM Na2-EDTA, pH 7.4, at a flow rate of 0.2 ml/min. Fractions of 1.0 ml were collected. The column was calibrated with human serum albumin and ultracentrifugally prepared lipoprotein fractions (VLDL, LDL, and HDL).
Analytical and preparative isotachophoresis. Analytical isotachophoresis (ITP) of lipoproteins was performed as described in detail previously (44, 45) . Briefly, serum was preincubated with the nonpolar dye Sudanblack B (1% solution in ethylene glycol added in a ratio of 2:1, vol/vol) for 30 min at 4VC, and mixed (2:1, vol/vol) with defined spacers. The final concentration of each spacer was 0.2 mg/ml. For separation 2 ,l of preincubated sample was used. The separation was carried out in the automated free flow capillary electrophoresis instrument, PACE 2000 (Beckman Instruments, Inc., Palo Alto, CA) using a teflon capillary with a diameter of 200 gm. The leading electrolyte contained 5 mM H3PO4, 20 mM ammediol, pH 9.2. The terminating electrolyte consisted of 50 mM E-aminocaproic acid, 20 mM ammediol, pH 10. The electrolyte solutions contained also 0.25% hydroxypropyl-methylcellulose to increase viscosity and to suppress undesired electroosmotic effects. The separated fractions were monitored at 570 nm.
Preparative free flow isotachophoresis of lipoproteins was carried out in an Elphor VAP 22 (Bender & Hobein, Munich, FRG) as described (44) . Leading and terminating electrolytes were identical as described above. 1 ml of serum was mixed with spacers (final concentration 1 mg/ml) and terminating buffer ( 1:3, vol/vol). The fractions collected were passed through a Sephadex G-25 PD-10 column (Pharmacia) to remove the isotachophoresis buffers and spacers for further analysis.
Determination ofLCA T activity. LCAT activity in fractions from preparative ITP or Superose was measured by a proteoliposome assay as previously described (46) . Proteoliposomes containing 600 nmol/ ml of l-palmitoyl-2-oleyl-lecithin (Fluka, Buchs, Switzerland), 25 nmol/ml of free cholesterol (Merck, Darmstadt, FRG), 4 (47) . Briefly, 6 ml of EDTA blood was obtained from normal controls and patients. Leukocytes were separated by density-gradient centrifugation. They were subsequently incubated at 4°C for 1 h with 10 ,g/ml rhodamine isothiocyanate (RITC)-conjugated HDL3. After washing, the leukocyte-bound HDL particles were determined by fluorescent flow cytometry. Specific binding was calculated by subtraction of binding in the presence of excess unlabeled HDL3 from total binding. Experiments with apoE-free '25I-labeled HDL3 were performed as described in detail previously (48) . Instead of macrophages, granulocytes were used for these determinations. Briefly, granulocytes were isolated from whole blood by density gradient centrifugation. Subsequently, 106 cells were incubated with '25I-labeled HDL3 for 1 h at 40C. Specific binding was calculated by substracting nonspecific binding in the presence of a 25-fold excess of unlabeled lipoprotein from total activity bound. LDL receptor assay. LDL receptors were determined on monocytes isolated from peripheral blood by a fluorescent flow cytometric method (49) . Monocytes were isolated from peripheral blood as described for the HDL-binding assay. Subsequently they were kept for 48 h in MEM supplemented with 10% lipoprotein deficient serum or 10% fetal calf serum. Then they were incubated with several concentrations ofa fluorescent labeled monoclonal antibody against the LDL receptor (C7). Finally, mean fluorescence was determined by flow cytometry. In addition, binding and degradation of 1251I-LDL by cultured fibroblasts were determined as described by Goldstein and Brown (50) .
Statistical analysis. Lipoprotein, apolipoprotein, and lipid values of controls and heterozygous members of the kindred were analyzed for significant differences with the paired t-test.
Results
Patient presentation. A girl of Turkish descent, now 11 yr of age, was presented to her pediatrician because of unusual xanthomas at the age of 7 yr. Her physical examination was absolutely inconspicuous except for yellow-orange xanthomas on the flexor sides of several joints (elbow, wrist, knee). At her initial presentation, she had no corneal opacities, no enlarged tonsils, no splenomegaly, and only mild hepatomegaly on ultrasound examination. However, during the last year she developed progressive corneal clouding detectable by slit lamp examination. Table I summarizes the lipoprotein and apolipoprotein determinations and important clinical findings of the propositus, her parents, and her sister. She has almost no cholesterol in the HDL fraction. ApoA-I was undetectable by routine assays. Gel electrophoresis after immunoprecipitation with apoA-I antibodies, and Western blotting revealed no apoA-I immunoreactive material. ApoA-II was -15% of normal. Most of the apoA-II was found in the HDL fraction and some in the lower density ranges. The only other striking abnormality in her lipoprotein profile is an elevated total cholesterol, which is due to an increase in LDL-cholesterol. This is accompanied by an increase in apoB-I00. It is important to note that neither apoC-Il nor apoA-IV levels were reduced.
Both her parents have low HDL-cholesterol and apoA-I levels, and a decreased ratio ofHDL-cholesterol to total cholesterol. Since they are first-degree cousins, it was assumed that they are heterozygous for the same genetic defect. The younger sister also has low HDL-cholesterol and apoA-I levels and is assumed to be heterozygous. No other overt lipoprotein abnormality was detected in these three probands.
Analysis ofintestinal RNA. ApoA-I is known to be synthesized in the liver and the small intestine; i.e., both tissues contain mRNA for apoA-I. A biopsy specimen from the duodenum of the HDL-deficient proband was taken after informed consent by her parents; -5-10 mg oftissue was obtained and shock frozen. The total material was used for RNA isolation. Control intestinal RNA was isolated from pooled diagnostic biopsies. These patients were biopsied for various gastroenterologic reasons. Northern blotting showed the presence of a normal-sized mRNA for apoA-I in the child's intestinal mucosa (Fig. 1) . The relative amount appears to be increased as compared to the normal controls. These experiments exclude a Fig.  3 A the nucleic acid sequence of exon 3 is illustrated. The inserted cytosine is marked by an arrow. Fig. 3 and the 2.2-kb apoA-I bands were seen. At higher stringency only the 2.2-kb band hybridized to PI. This experiment provides evidence that the 2.2-kb PstI fragment contains the cytosine insertion. It also proves that the insertion is on the same allele which the HDL-deficient proband inherited from her father.
Since the background of oligonucleotide melting on total genomic DNA was substantial, we decided to analyze the DNA of the other family members after amplification of exon 3 of the apoA-I gene. A 317 bp fragment containing exon 3 was amplified using P2 and P3 as primers. The amplified DNA was applied to a nitrocellulose filter and hybridized to P1 under stringent conditions which permit only hybridization to the mutant allele (Fig. 4) . The amplified DNA from 15 members ofthe family (including the propositus and her parents) hybrid- ized to P1 under these conditions, indicating the presence of at least one mutant allele.
The "wild type" oligonucleotide was not suitable for oligonucleotide melting even with cloned DNA (data not shown). Therefore, amplified DNA from exon 3 of the patient was sequenced after subcloning into pUC 18 in order to prove that she is homozygous for the cytosine insertion. When eleven independent clones were sequenced, all of them contained the additional cytosine base (Fig. 5) . This constellation has a probability of 1:2,048 in a heterozygous individual and is taken as evidence for homozygosity.
The family members were categorized as heterozygotes when the mutant allele was present and serum apoA-I was de- No family member with HDL-cholesterol > 40 mg/dl or apoA-I > 100 mg/dl has the cytosine insertion, whereas all but one of the others have the mutant allele. The homozygote proband has no apoA-I and almost no HDL-cholesterol. This is evidence that the mutation represents an autosomal dominant trait with a gene dosage effect. One individual with an HDLcholesterol of 26 mg/dl and an apoA-I of 93 mg/dl, does not have the cytosine insertion according to oligonucleotide melting. His haplotype is aI-6/9. Since the cytosine insertion cosegregates with allele al-1, his cause for low HDL-cholesterol and apoA-I must be different from the apoA-I mutation described here. Fig. 6 represents a pedigree of the family. Family members heterozygous for the cytosine insertion are shown with halffilled symbols. The homozygous proband is shown by the filled circle.
Analysis ofLDL receptor activity. Hypercholesterolemia in the proband is most likely not caused by an LDL receptor defect, since both her parents have normal LDL-cholesterol. To ascertain this assumption, LDL receptors were determined by a fluorescence flow cytometric method in monocytes and by conventional binding of iodine labeled LDL to fibroblasts. As (Fig. 7) .
Since we had observed a postprandial decrease of RITC-HDL binding to Tangier and normal leukocytes, a similar experiment was performed in HDL deficiency with xanthomas. First, postprandial changes of apolipoprotein levels in plasma were analyzed. Data from other laboratories indicate that serum apoA-IV increases, whereas apoA-I and apoA-II do not change significantly. HDL apoA-I declines (52, 53) . After a standard fat meal ( 1,600 kcal, 70% fat) there was a small increase in plasma apoA-I and a decrease of HDL apoA-I in normal controls. In contrast, in a Tangier patient there was an almost threefold increase in plasma apoA-I (from 5.8 to 14.6 mg/dl 5 h postprandial). No apoA-I is detectable in the proband's fasting and postprandial plasma. Plasma apoA-IV increases in controls, Tangier patients and the proband similarly (from 16 to 25 mg/dl). ApoA-II increases in Tangier patients (from 9.5 to 23 mg/dl), whereas there is no major change in controls and the proband. The increase in apoA-I in Tangier patients is most likely related to apoA-I secreted with chylomicrons. Thus, there is a substantial increase in apoA-Icontaining particles postprandially in Tangier disease which may bind to cellular receptors.
When HDL binding to leukocytes isolated either in the fasting or postprandial state was analyzed, a decrease in binding of normal '251-HDL and RITC-HDL to postprandial Tangier leukocytes was observed. In HDL deficiency with xanthomas no effect of the postprandial state on HDL-binding was observed (Figs. 7 and 8 ). Since Tangier patients secrete normal chylomicrons, this was interpreted as competition of postprandial apoA-I containing particles with labeled HDL3 for cellular HDL-binding sites.
Analysis oflipoproteins by gelfiltration. ApoA-IV concentration in the homozygous proband was shown to be normal. However, the distribution ofapoA-IV among lipoproteins separated by gel filtration differed from normal subjects. There was substantially less apoA-IV lipoprotein associated in the HDLdeficient serum (13% vs. 25%). Also the apoA-IV containing particles were smaller indicating a higher density (Fig. 9 A) .
Distribution of LCAT activity was not substantially different between normal serum and serum of the HDL-deficient proband. However, it appeared that more activity was not associated (51% vs. 44%) with lipoprotein particles (Fig. 9 B enriched in apoA-II and apoE. Peaks 4-6 contain most of apoA-IV (-69%) and most ofLCAT (-75%) in HDL (44) . The apoB-containing particles are separated into eight fractions (45 ) . Peak 7 represents chylomicrons, peaks 8-10 represent VLDL and remnant particles, peaks 1 1-14 represent LDL particles. When analytical ITP of serum from the patient with HDL deficiency with xanthomas is compared to serum from normal and Tangier disease (Fig. 10) , it is obvious that there is almost complete absence of fractions 1 and 2. Fraction 3 is significantly lower than in normal, but there is some material present. Compared to Tangier disease, peaks 1 and 2 appear to be even smaller, whereas there is more lipoprotein in peak 5. The other relevant finding is the small amount of lipoprotein particles in the remnant fractions (peaks 8-10) in HDL deficiency with xanthomas. On the other hand there is an increase in the LDL fractions, particularly peaks 13 and 14. This is completely different from Tangier disease, where triglyceride rich particles accumulate, but LDL is reduced. This is probably related to decreased lipoprotein lipase activity in Tangier disease (25) . Analytical ITP does not permit quantitation ofapolipoproteins and other components within the single fractions. Thus, preparative ITP was performed. There were only traces ofapolipoproteins and lipids in the area corresponding to normal fast-migrating HDL (peaks 1 and 2). In the intermediate migrating HDL (peak 3) a small amount of apoA-II, phospholipids (7.2% of total serum phospholipids) and cholesterol (0.6% oftotal cholesterol) was found (Table III) . This subfraction also contained apoA-IV (Table IV) . The slow migrating HDL subpopulations contained most of the HDL associated apoA-IV, apoA-II, apoE and a small amount of phospholipids (3.7% oftotal) and cholesterol (0.5% oftotal cholesterol). This Fraction Number Figure 9 . Gel filtration elution profiles of apoA-IV (A) and LCAT (B) from normal and HDL deficiency serum. Lipoprotein associated ApoA-IV in HDL deficiency is only half that found in normal ( 13% vs. 25%). In addition, it elutes later, i.e., as a smaller particle. LCAT also appears to be less lipoprotein associated and elutes with smaller particles. However, this is not as striking as with apoA-IV.
These data indicate that the residual particles found in HDL in the proband's plasma are most likely (a) apoE/apoA-II particles within the slow-migrating HDL population and (b) apoA-IV/LCAT particles within the intermediate and slowmigrating HDL population. However, due to the complete absence of apoA-I, all HDL populations are severely reduced. The shift of HDL protein constituents into other lipoprotein fractions or into the non-lipoprotein serum protein pool may have important metabolic consequences.
Discussion
The genetic defect leading to HDL deficiency with xanthomas in a Turkish kindred has been analyzed. Cloning and sequencing of the mutant apoA-I allele revealed that there is a cytosine insertion in the third exon of the apoA-I gene. This insertion leads to a frameshift so that the open reading frame codes for a hypothetical translation product which is only 57 amino acids long. The propositus could be shown to be homozygous for the mutation.
There were four more base substitutions compared to the published gene sequence found. All these differences were located in introns or in the 3' untranslated region. Thus, they
High Density Lipoprotein Deficiency with Xanthomas 2269 cannot influence the primary structure ofthe translation product. Interference with expression or splicing ofthe apoA-I gene is unlikely for two reasons. First, the Northern blot experiment showed that the apoA-I mRNA ofthe HDL-deficient proband is of normal size. And secondly, the presence of reasonable amounts of apoA-I message also precludes a defect in apoA-I gene expression as the cause for apoA-I deficiency. In fact, the number of differences observed is less than that between two previously published sequences ( 14, 54) , so that we assume that this represents the normal variability of the apoA-I gene locus.
Pedigree analysis showed that the cytosine insertion cosegregates with low HDL in this family. All individuals within the pedigree who were heterozygous for the cytosine insertion had apoA-I levels < 100 mg/dl and HDL-cholesterol < 40 mg/dl. 44 ).
scribed here is caused by the inability to synthesize apoA-I, the major apolipoprotein of HDL. There have been more "asynthetic" cases described in the literature. They differ from this case in several respects. In two cases the apoC-III gene or both the apoC-Il and the apoA-IV genes are affected in addition to the apoA-I gene (27, 28) . There are important metabolic differences to apoA-I/ apoC-11 deficiency and apoA-I/apoC-III/apoA-IV deficiency. In contrast to the case described here, the patients with additional apoC-III deficiency have low VLDL and IDL with normal or low LDL cholesterol (55, 56) . Both syndromes show complex abnormalities of lipoprotein metabolism, therefore the mechanisms leading to a different lipoprotein pattern from our patient remain unresolved.
There have been two other patients described with pure apoA-I deficiency (29, 57, 58) . One patient (29, 57) has also severely decreased apoC-Il and apoC-II and no hypercholesterolemia. In fact, the initial presentation ofthis case was as apoA-I/apoC-III deficiency (57) . The reason for the decreased apoC-III in this patient has not been elucidated. The low apoC-III provides evidence for a potentially important role of apoC-III in the pathogenesis of hypercholesterolemia in apoA-I deficiency. Unfortunately, there are no detailed data about her first degree relatives available, so that the exact mode ofinheritance is not known.
The genetic defect of the patient described by Gustafson et al. (58) could not be analyzed. Thus, it is not known, whether this patient is similar to the patient described here. The patient had also planar xanthomas and corneal clouding. ApoC-III was normal or even slightly elevated. Different from our proband, this patient had hypertriglyceridemia.
In the patient described here, lipoprotein determinations show two striking abnormalities: one is the lack of HDL, and the other is hypercholesterolemia. The lack of HDL is a direct consequence of the inability to synthesize apoA-I. On analytical and preparative ITP as well as fractionation by superose chromatography, it was demonstrated, that the small amount of lipoproteins in the HDL density range is mainly composed of apoE, apoA-II, and apoA-IV-containing particles. The data obtained by superose chromatography indicate that the percentage ofapoA-IV, which is lipoprotein associated is only half of normal. This is probably related to the complete lack of normal HDL particles. The apoA-IV particles may account for part of the HDL cholesterol measured in the child's serum. However, the correlation may be confounded by the fact that apoA-IV particles may not be stable on ultracentrifugation.
Serum LDL is increased, whereas VLDL is low in our patient. This increase in LDL is enough to be reflected in an increased total serum cholesterol. On analytical ITP, there is an increase in the fractions corresponding to LDL (11) (12) (13) (14) , whereas the remnant fractions (8) (9) (10) are reduced. This indicates efficient conversion of remnant particles to LDL. The reason for the increased LDL-cholesterol is not entirely clear. It is not caused by a defect in the LDL receptor. In addition, it is unlikely that another genetic defect (e.g., apoB-3500) is responsible, since neither parent has an increased LDL cholesterol. There are two factors that may explain the increased LDL cholesterol. One is the lack of HDL, with a subsequent redistribution of C-apolipoproteins. Since apoC-III levels are normal in the HDL-deficient patient, one may assume that apoC-III and the other C-apolipoproteins are predominantly associated with apoB-containing particles. C-Apolipoproteins are known to interfere with the uptake of remnant particles. It is believed that apoC-III inhibits binding of apoE to its specific receptor (59) (60) (61) . The reduced clearance of remnant particles could lead to an increased production rate of LDL, provided that lipolysis proceeds efficiently. As discussed above, the lack of remnant accumulation shown by analytical ITP supports this hypothesis. This is different to the situation in familial dysbetalipoproteinemia with an accumulation of f3-VLDL but low LDL-cholesterol (62) . Also HDL deficiency in Tangier patients is not accompanied by high LDL levels. These patients obviously cannot convert triglyceride-rich particles normally (25) .
The second factor may be complete transfer of cholesteryl esters into VLDL, IDL, and LDL. This situation is opposite to CETP deficiency, where transfer of cholesterol esters from HDL to VLDL or IDL is severely impaired. Cholesterol esters accumulate in HDL. This leads to the formation of apoE rich HDLc, that may be cleared by the apoB/E or the apoE receptor. Interestingly, these patients have low apoB-associated cholesterol (33) . In HDL deficiency with xanthomas cholesterol effilux from peripheral cells is impaired. The plasmatic cholesterol acceptor is not known with certainty. Possibly, excess cellular cholesterol is removed by an apoA-IV/LCAT particle. This cholesterol would then have to be rapidly transferred onto triglyceride-rich particles, because the initial acceptor particles are unstable. This mechanism increases cholesterol and cholesteryl esters in remnant like particles and contributes to the increased flux into LDL.
We propose two mechanisms which may contribute to the increased LDL levels in HDL deficiency with xanthomas. First there is increased efflux of cholesteryl esters into the VLDL/ IDL density fraction. Second there is impaired removal ofremnant particles with rapid conversion of these particles to LDL. The increased production of LDL may lead to downregulation ofan otherwise normal LDL receptor pathway. Metabolic studies and in vitro studies with lipoproteins isolated from the HDL-deficient patient are necessary to prove this hypothesis.
The lack of HDL particles has important consequences for lipoprotein metabolism. This is similar to the other HDL deficiency syndromes. The complete lack ofapoA-I permits analysis of the relative importance of apoA-I in the interaction of lipoproteins with cells. In our assay system for HDL binding to the cell surface, specific binding of HDL particles to leukocytes is reduced in the postprandial state. This is seen with postprandial leukocytes from normal probands as well as from Tangier patients. It is likely that this effect is caused by the appearance of apoA-I-rich postprandial particles with high affinity to cell surface receptors. When postprandial leukocytes from the HDL-deficient patient are used in this assay, no difference to fasting leukocytes is observed, even though apoA-IV and apoA-II increase in the postprandial phase. This is taken as evidence that apoA-I-rich postprandial particles compete for cell surface binding sites with labeled HDL3 particles.
Due to the lack of the major ligand for HDL binding, there is a defect in reverse cholesterol transport in our patient. There may still be some cholesterol uptake by the remaining apoA-IV/LCAT particles and possibly by apoE/apoA-II particles. The efficacy of this process has not been analyzed so far. We have no direct evidence that there is direct uptake offree cholesterol by apoB particles with subsequent esterification within this density range.
The cardiovascular risk of the kindred presented is difficult to assess in comparison to the other HDL-deficiency syn-dromes. The homozygous proband is still a child and has no signs of CVD. The oldest heterozygotes alive are in their late 40s and early 50s. They do not have symptoms of CVD. Since these people live in a remote area ofTurkey, it was not possible to obtain more sophisticated cardiologic tests on them (e.g. stress tests, thallium scans, etc.). The obligate heterozygous individual 11-3 died suddenly at the age of 62. Whether this was due to CVD cannot be determined anymore. Thus, to obtain a more reliable assessment ofcardiovascular risk, it will be necessary to follow this family for several years.
Metabolic studies in vivo are necessary to supplement the in vitro studies presented here. They will permit a more detailed description ofthe factors contributing to hypercholesterolemia in the proband. The analysis of apoB metabolism and its postprandial changes will be of particular interest.
